The Jaypirca application moves to the EC for a decision, expected within the next one to two months.

Curis plans to dose the initial five patients by the end of July 2026, with data anticipated in December 2026.

Daniel Ermann, MD, discusses treatment considerations with newly diagnosed older/elderly patients with chronic lymphocytic ...

Daniel Ermann, MD, highlights 6.5-year follow-up data for zanubrutinib from the phase 3 SEQUOIA trial, which compared the BTK ...

Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive ...

Adding a non-covalent BTK inhibitor improved progression-free survival ...

Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of ...

Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults and is currently incurable. Dr. Brian Koffman, chief medical officer and executive vice president of the CLL ...

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...

Eli Lilly LLY shares ended the last trading session 7.1% higher at $1. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to ...

In today's ACT Brief, we recap key themes from DIA 2026 on operational priorities and regulatory shifts, examine ...

Propensity-matched TriNetX cohorts (669 pairs) of TP53–wild-type, treatment-naive CLL showed venetoclax–obinutuzumab improved TTNT and 4-year OS versus acalabrutinib (HR 1.84). Median TTNT was 47.7 ...